KR102714760B1 - Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 - Google Patents

Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 Download PDF

Info

Publication number
KR102714760B1
KR102714760B1 KR1020247004922A KR20247004922A KR102714760B1 KR 102714760 B1 KR102714760 B1 KR 102714760B1 KR 1020247004922 A KR1020247004922 A KR 1020247004922A KR 20247004922 A KR20247004922 A KR 20247004922A KR 102714760 B1 KR102714760 B1 KR 102714760B1
Authority
KR
South Korea
Prior art keywords
vwf
amino acids
domain
fviii
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247004922A
Other languages
English (en)
Korean (ko)
Other versions
KR102714760B9 (ko
KR20240023705A (ko
Inventor
엑타 세스 차브라
존 쿨맨
통야오 리우
Original Assignee
바이오버라티브 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오버라티브 테라퓨틱스 인크. filed Critical 바이오버라티브 테라퓨틱스 인크.
Priority to KR1020247032926A priority Critical patent/KR102865153B1/ko
Publication of KR20240023705A publication Critical patent/KR20240023705A/ko
Application granted granted Critical
Publication of KR102714760B1 publication Critical patent/KR102714760B1/ko
Publication of KR102714760B9 publication Critical patent/KR102714760B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020247004922A 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 Active KR102714760B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247032926A KR102865153B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361840872P 2013-06-28 2013-06-28
US61/840,872 2013-06-28
PCT/US2014/044731 WO2014210558A1 (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof
KR1020227045978A KR20230007555A (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045978A Division KR20230007555A (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032926A Division KR102865153B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Publications (3)

Publication Number Publication Date
KR20240023705A KR20240023705A (ko) 2024-02-22
KR102714760B1 true KR102714760B1 (ko) 2024-10-11
KR102714760B9 KR102714760B9 (ko) 2025-09-15

Family

ID=52142742

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247004922A Active KR102714760B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020227045978A Ceased KR20230007555A (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020247032926A Active KR102865153B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020157033268A Active KR102666819B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227045978A Ceased KR20230007555A (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020247032926A Active KR102865153B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020157033268A Active KR102666819B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Country Status (17)

Country Link
US (3) US20160251408A1 (enExample)
EP (2) EP4368194A3 (enExample)
JP (6) JP2016523919A (enExample)
KR (4) KR102714760B1 (enExample)
CN (3) CN113817069A (enExample)
AU (3) AU2014302100B2 (enExample)
CA (1) CA2913078A1 (enExample)
CL (1) CL2015003710A1 (enExample)
EA (1) EA201592022A1 (enExample)
HK (1) HK1223302A1 (enExample)
IL (3) IL242436B (enExample)
MX (1) MX2015016567A (enExample)
NZ (1) NZ713904A (enExample)
PH (1) PH12015502614A1 (enExample)
SG (3) SG11201509313PA (enExample)
TW (3) TWI716340B (enExample)
WO (1) WO2014210558A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
EA035323B1 (ru) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
DK3091997T5 (da) * 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
AU2016231328B2 (en) * 2015-03-06 2018-07-05 CSL Behring Lengnau AG Compounds for improving the half-life of von Willebrand factor
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
TW201828975A (zh) * 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146782A1 (en) 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
US20110183907A1 (en) 2008-06-24 2011-07-28 Thomas Weimer Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
US20150266943A1 (en) 2012-07-11 2015-09-24 Amunix Operating Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
EP0253870B1 (en) 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2003526625A (ja) * 1999-07-23 2003-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血小板の活性化の調節
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001087922A2 (en) 2000-05-16 2001-11-22 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
CN100343393C (zh) 2002-03-15 2007-10-17 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
WO2004076484A1 (en) * 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
KR20080071119A (ko) 2005-08-12 2008-08-01 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
AU2007294805A1 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP3231440A1 (en) * 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
BRPI0820271A2 (pt) * 2007-11-09 2015-05-26 Baxter Int Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
WO2010091122A1 (en) * 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
AU2010258892B2 (en) 2009-06-08 2015-08-13 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
JP5544219B2 (ja) * 2009-09-24 2014-07-09 富士フイルム株式会社 内視鏡システム
MX2012005527A (es) * 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
MX353233B (es) * 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
WO2011084808A2 (en) * 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
EA035323B1 (ru) * 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
HRP20221531T1 (hr) * 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
WO2014210547A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker
DK3091997T5 (da) * 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
RS66972B1 (sr) * 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146782A1 (en) 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
US20110183907A1 (en) 2008-06-24 2011-07-28 Thomas Weimer Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
US20150266943A1 (en) 2012-07-11 2015-09-24 Amunix Operating Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature Biotech., Vol. 27, No. 12, pp.1186-1190 (2009. 11. 15.)

Also Published As

Publication number Publication date
IL266462B (en) 2022-12-01
KR102666819B1 (ko) 2024-05-23
TWI716340B (zh) 2021-01-21
CN113817069A (zh) 2021-12-21
TW202313672A (zh) 2023-04-01
CN105392495A (zh) 2016-03-09
AU2014302100B2 (en) 2020-02-13
US20240083975A1 (en) 2024-03-14
IL297611A (en) 2022-12-01
IL297611B1 (en) 2025-07-01
EP4368194A3 (en) 2024-07-31
JP2016523919A (ja) 2016-08-12
IL242436B (en) 2019-05-30
JP2022000053A (ja) 2022-01-04
KR20230007555A (ko) 2023-01-12
IL266462B2 (en) 2023-04-01
MX2015016567A (es) 2016-03-31
IL266462A (en) 2019-06-30
KR20160023654A (ko) 2016-03-03
EP4368194A2 (en) 2024-05-15
CL2015003710A1 (es) 2016-08-26
AU2014302100A1 (en) 2015-11-26
CA2913078A1 (en) 2014-12-31
AU2020203063B2 (en) 2023-05-25
CN113831415A (zh) 2021-12-24
EP3013358A1 (en) 2016-05-04
TWI770467B (zh) 2022-07-11
EA201592022A1 (ru) 2016-05-31
KR102865153B1 (ko) 2025-09-29
NZ713904A (en) 2022-02-25
AU2023219840A1 (en) 2023-09-14
JP2019010124A (ja) 2019-01-24
JP7005800B2 (ja) 2022-02-10
EP3013358A4 (en) 2017-03-22
BR112015031194A2 (pt) 2017-09-19
AU2020203063A1 (en) 2020-05-28
TW201514204A (zh) 2015-04-16
SG10201913738YA (en) 2020-03-30
JP2025061316A (ja) 2025-04-10
WO2014210558A1 (en) 2014-12-31
HK1223302A1 (zh) 2017-07-28
KR20240148954A (ko) 2024-10-11
US20160251408A1 (en) 2016-09-01
SG11201509313PA (en) 2016-01-28
JP7297837B2 (ja) 2023-06-26
PH12015502614A1 (en) 2016-02-29
US20220106383A1 (en) 2022-04-07
JP7623426B2 (ja) 2025-01-28
JP2023107932A (ja) 2023-08-03
IL297611B2 (en) 2025-11-01
KR102714760B9 (ko) 2025-09-15
TW202045535A (zh) 2020-12-16
KR20240023705A (ko) 2024-02-22
TWI844042B (zh) 2024-06-01
JP2021072853A (ja) 2021-05-13
SG10201710616XA (en) 2018-02-27

Similar Documents

Publication Publication Date Title
KR102714760B1 (ko) Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR102409250B1 (ko) 인자 viii 키메라 단백질 및 이들의 용도
KR102212098B1 (ko) 키메라 인자 viii 폴리펩티드들과 이의 용도
KR20210020030A (ko) A형 혈우병의 치료 방법
US20160229903A1 (en) Thrombin cleavable linker
KR102175878B1 (ko) Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
EA041588B1 (ru) Расщепляемый тромбином линкер, содержащий xten, и его применение
BR112015031194B1 (pt) Molécula quimérica, composição farmacêutica, e uso dos anteriores

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20250828

Appeal event data comment text: Appeal Kind Category : Correction, Appeal Ground Text : 2714760

Appeal request date: 20250805

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2025105000073

PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20250915

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1027147600000

Gazette reference publication date: 20241011